Psychedelics Researchers & Industry Leaders Weigh In On Groundbreaking PTSD Treatment News
Portfolio Pulse from Lara Goldstein
The Multidisciplinary Association for Psychedelic Studies (MAPS) and its subsidiary MAPS PBC have published results from a Phase 3 study on MDMA-assisted therapy for PTSD, showing significant reduction in symptoms. The therapy is expected to be considered for FDA approval in 2024. If approved, the DEA would reschedule MDMA for prescription medical use. Numinus Wellness (OTC:NUMIF), a MAPS research partner, has hailed the results as a significant milestone for the healthcare and psychedelic industries.
September 15, 2023 | 9:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Numinus Wellness, a research partner of MAPS, could benefit from the potential FDA approval of MDMA-assisted therapy for PTSD.
As a research partner of MAPS, Numinus Wellness stands to benefit from the potential FDA approval of MDMA-assisted therapy for PTSD. This could lead to increased recognition and potential growth for the company.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80